Literature DB >> 31336479

Association of diabetic foot ulcers with chronic vascular diabetic complications in patients with type 2 diabetes.

Magdy H Megallaa1, Azza A Ismail1, Mohammed H Zeitoun1, Mai S Khalifa2.   

Abstract

CONTEXT: Diabetes mellitus is a common disease which is prevalent globally, presenting with chronic complications and constitutes a major risk to the patient. Diabetic foot ulcers are the single biggest risk factor for non-traumatic lower limb amputations in persons with diabetes. We aimed to screen for the chronic vascular diabetic complications in patients with diabetic foot ulcers (DFUs) and to assess the association of diabetic foot ulcers with these complications in the study group. SUBJECTS AND METHODS: This cross-sectional study included 180 type 2 diabetic patients (aged 30-70 years) with diabetic foot ulcers who attended the Outpatient Clinic of Diabetes in Alexandria Main University Hospital. Full diabetic foot examination was done to all study subjects. DFUs were assessed using University of Texas Diabetic Wound Classification System. HbA1c, LDL-C, serum creatinine, and urinary albumin creatinine ratio (ACR) were measured for all study subjects. Estimated glomerular filtration rate (eGFR) was calculated using CKD-EPI equation. Fundus examination was done for all study subjects.
RESULTS: The prevalence of diabetic kidney disease (DKD) and diabetic retinopathy (DR) was 86.1% and 90% respectively among the study group. 86.7% of patients had neuropathic DFUs, 11.1% of them had ischemic DFUs and 2.2% had neuro-ischemic DFUs. Regarding diabetic peripheral neuropathy (DPN) and peripheral arterial disease (PAD) as risk factors for developing DFU, the prevalence of both of them respectively was 82% and 20% among the study group. There was statistically significant association between both DKD, DR and peripheral neuropathy. There was also statistically significant association between both DKD, DR and peripheral arterial disease (PAD).
CONCLUSION: Chronic vascular diabetic complications are common among type 2 diabetic patients with diabetic foot ulcers. There is statistically significant association between these complications and diabetic peripheral neuropathy (DPN) and peripheral arterial disease (PAD).
Copyright © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetic foot ulcer; Type 2 diabetes; Vascular complications.

Year:  2019        PMID: 31336479     DOI: 10.1016/j.dsx.2019.01.048

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  5 in total

1.  Associations of Estimated Glomerular Filtration Rate with All-Cause Mortality and Cardiovascular Mortality in Patients with Diabetic Foot Osteomyelitis.

Authors:  Jianhao Huang; Weiwei Li; Suosu Wei; Xing Zhou; Yuechou Nong; Jingxia Sun; Zhenwei Zhai; Wensheng Lu
Journal:  Int J Gen Med       Date:  2021-08-14

Review 2.  An Overview of Diabetic Foot Ulcers and Associated Problems with Special Emphasis on Treatments with Antimicrobials.

Authors:  Mirza Shahed Baig; Ahmadi Banu; Mehrukh Zehravi; Ritesh Rana; Sushil S Burle; Sharuk L Khan; Fahadul Islam; Falak A Siddiqui; Ehab El Sayed Massoud; Md Habibur Rahman; Simona Cavalu
Journal:  Life (Basel)       Date:  2022-07-14

3.  Engineering diabetic human skin equivalent for in vitro and in vivo applications.

Authors:  Atieh Abedin-Do; Ze Zhang; Yvan Douville; Mirelle Méthot; Julien Bernatchez; Mahmoud Rouabhia
Journal:  Front Bioeng Biotechnol       Date:  2022-09-30

4.  Efficacy of Mudan Granule (Combined With Methylcobalamin) on Type 2 Diabetic Peripheral Neuropathy: Study Protocol for a Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm, Multi-Center Trial.

Authors:  Yuehong Zhang; Yingying Duan; Rui Hao; Keyu Chen; Tongyue Yu; Fengmei Lian; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 5.  Fibroblast Growth Factor in Diabetic Foot Ulcer: Progress and Therapeutic Prospects.

Authors:  Ye Liu; Yiqiu Liu; Junyu Deng; Wei Li; Xuqiang Nie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-14       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.